PAN Launches a New Financial Assistance Program, Offering Help and Hope to Patients with Progressive Neuroendocrine Tumors of Pancreatic Origin
Washington, DC, May 31, 2013 – Patient Access Network (PAN) Foundation has launched its newest financial assistance program designed to alleviate the out-of-pocket costs for specialty medications used to target progressive neuroendocrine tumors of pancreatic origin (PNET). This program marks the Foundation’s 10th financial assistance program in 2013.
“The development of targeted therapies to treat progressive neuroendocrine tumors of pancreatic origin means patients have a better chance of surviving,” explained Patrick McKercher, PAN President. “We are all dedicated to ensuring that patients have the best chance of survival, which often means they need access to specialty medicines that may result in high out-of-pocket costs for patients – that’s where PAN comes in.”
Qualifying patients are eligible to receive $7,500 per year to cover costs associated with their specialty medications. Patients must have insurance that covers the medication for which they are seeking assistance, must have a household income less than or equal to 500% of the Federal Poverty Level and must reside and receive treatment in the United States.
About Progressive Neuroendocrine Tumors of Pancreatic Origin
Pancreatic neuroendocrine tumors, also called islet cell tumors, are rare tumors that form from the hormone-producing cells in the pancreas called islet cells. Pancreatic neuroendocrine tumors are either functional, which means that they cause overproduction of hormones, or nonfunctional (produce no hormones). Most functional neuroendocrine tumors are benign. However, approximately 90% of nonfunctional neuroendocrine tumors are cancerous. Symptoms vary depending on the type of pancreatic neuroendocrine tumor. Functional pancreatic neuroendocrine tumors may cause the pancreas to overproduce certain hormones, such as insulin or glucagon. High hormone levels in the blood results in symptoms including weight loss, nausea, vomiting, muscle weakness and skin rash. Nonfunctional pancreatic neuroendocrine tumors do not overproduce pancreatic hormones. They are generally detected because of pain or jaundice caused by the large size of the tumor.
About the PAN Foundation
Patient Access Network Foundation is dedicated to providing help and hope to patients who would otherwise be unable to afford high-cost specialty medications. PAN envisions a society in which every individual can access needed medical care, offering hope for a healthy tomorrow. PAN provides assistance through nearly 50 disease-specific programs designed to help patients being treated for certain cancers, chronic illnesses, and rare diseases. Through our streamlined application process and state of the art online tools, we are able to ensure that patients are put on the fast track to therapy.